Atherosclerosis Drugs Market to Reach USD 26.9 Billion by 2032, Growing at 2.8% CAGR Forecast Report

DETROIT - Oct. 10, 2025 - PRLog -- Acumen Research And Consulting today announced the release of its comprehensive Atherosclerosis Drugs Market Report, offering deep insights into market size, share, growth, analysis, and trends for 2023–2032. The forecast reveals moderate yet steady expansion driven by the rising global burden of cardiovascular disease, advances in drug development, and evolving therapeutic strategies.

Key Statistics from the Atherosclerosis Drugs Market

• Base Market Value (2022): USD 20.5 Billion
• Projected Market Value (2032): USD 26.9 Billion
• Compound Annual Growth Rate (CAGR, 2023–2032): 2.8%
• North America Share (2022): ~41% of global market
• Regional Growth Outlook: Asia-Pacific expected to grow at ~3.9% CAGR
• Leading Drug Class (2022): Anti-platelet medications

Market Overview & Dynamics

The Atherosclerosis Drugs Market comprises pharmaceutical agents aimed at managing or reducing atherosclerosis—the accumulation of plaques in arterial walls that contributes to cardiovascular disease. Key therapeutic classes in this market include statins, antiplatelet agents, cholesterol-lowering medications, ACE inhibitors, and others. Increasing prevalence of hypertension, high cholesterol, diabetes, obesity, and aging populations continues to drive demand for these therapies.

Recent trends such as personalized medicine, combination therapies, and targeted drug delivery are shaping the Atherosclerosis Drugs Market Trends. The emphasis on reducing side effects and improving patient adherence is raising the bar for innovation in formulations and delivery systems.

Download Free PDF Report: https://urlr.me/wKATrp

Regional & Competitive Landscape

In terms of Market Share, North America is the largest region, having captured around 41% of the atherosclerosis drugs market in 2022. This dominance is backed by strong healthcare infrastructure, established pharmaceutical presence, and high cardiovascular disease awareness.

Asia-Pacific is anticipated to be the fastest-growing region over the forecast period, with a projected CAGR near 3.9%. Factors supporting this growth include expanding healthcare access, rising incidence of lifestyle-related diseases, and growing pharmaceutical investment.

Key Players:

• Pfizer
• AstraZeneca
• Novartis
• Sanofi
• Merck & Co.
• Bristol-Myers Squibb
• Amgen
• Regeneron
• Eli Lilly
• Daiichi Sankyo
• Johnson & Johnson
• Bayer AG

Why This Report Matters

With the Atherosclerosis Drugs Market Size expected to climb from USD 20.5 billion in 2022 to USD 26.9 billion by 2032, this report offers key value to:

• Pharmaceutical companies planning drug development or market entry
• Healthcare policy makers and institutions assessing future cardiovascular burden

Read full news at Globenewswire: https://www.globenewswire.com/news-release/2023/10/02/2752937/0/en/Atherosclerosis-Drugs-Market-Size-is-expected-to-reach-USD-26-9-Billion-by-2032-registering-a-CAGR-of-2-8-from-2023-to-2032.html